



	Number at risk (number censored)						
Placebo group	22 (0)	22 (0)	21 (1)	19 (2)	19 (3)	18 (3)	18 (17)
Lanreotide group	22 (0)	21 (1)	18 (4)	13 (4)	13 (4)	13 (4)	11 (13)

Figure 2. Kaplan-Meier estimates of progression-free survival for the secondary outcome time to tumour progression based on significant increase in tumour volume (ie, $\geq 20\%$). Tick marks indicate censored data. Outcome data at time of censoring was available for all participants. Time to progression was compared between groups using the stratified log-rank test, with stratification for presence or absence of documented tumour growth at baseline. The hazard ratio was derived from a Cox proportional-hazards model with terms for study treatment and tumour growth at baseline; there was no statistically significant interaction between these terms. NR=not reached.